what is tms? 9-45 - the use of transcranial magnetic... · • 4 large, multisite, randomized...
Post on 28-Feb-2020
0 Views
Preview:
TRANSCRIPT
7/15/19
1
tmshealthsolutions.com
Transcranial Magnetic Stimulation for Treatment-Resistant OCD
Ryan Vidrine, MD Director of TM SHS OCD Program
UCSF Asst Professor of Psychiatryrvidrine@ tm shealthsolutions.com
IOCDF Conference July 2019Austin, Tx
tmshealthsolutions.com
• What is TMS?
• TMS for Depression (in brief)
• Formulation & Neurobiology of OCD
• Proposed TMS Targets of Stimulation, TMS Protocol, & Mechanism of Action
• Efficacy from FDA Clearance Study
• TMS Health Solutions –Private Practice Data/Outcomes
• Selecting OCD Patients for TMS & Insurance Coverage
• Patient Testimonials & Q&A
What to Expect from this talk:
tmshealthsolutions.com
What is TMS? Transcranial Magnetic Stimulation
7/15/19
2
tmshealthsolutions.com
Based on Faraday Principle
• Rapidly fluxing magnetic field
• Induces electric current in underlying cortex
• Electric field --> depolarization of neurons
• Allows focal manipulation of cortical activity
• Excitatory or Inhibitory
tmshealthsolutions.com
tmshealthsolutions.com
rTMS: Figure 8 coil
Focused Magnetic Field
7/15/19
3
tmshealthsolutions.com
Deep TMS: H shaped CoilBrainsway
Diffuse Magnetic Field
tmshealthsolutions.com
What does a course of TMS look like for patients?
Intake
Daily TMS Treatments plus Weekly Check-ins
End TMS
Start of TMS
Post TMS Check-ins
Week One
Week Two Week Three-Eight Week
Nine
TIME
• Adm inistered in sessions lasting approxim ately 20-40 m inutes, five tim es a w eek, over a period of 4-6 w eeks
• No anesthesia or sedation is required and patients can resum e their usual activities (including w ork) im m ediately
• M ost responders show signs of response by the 2nd or 3rd w eek
tmshealthsolutions.com
TMS: Contraindications
• Non-removable metallic objects in or around the head
• Conductive, ferromagnetic or other magnetic sensitive metals that are implanted or are non-
removable within 30 cm of treatment coil
• Implanted electrodes/ stimulators
• Deep Brain Stimulator
• Aneurysm clips or coils
• Cochlear implants
• Stents
• Bullet or other metal fragments
• Metallic tattoos
N euroS ta r T M S T herapy S ys tem U ser M anua l. N eurone tics , Inc : M a lve rn , P A .
7/15/19
4
tmshealthsolutions.com
TMS: Side Effects
• Headache
• Scalp sensitivity
• Syncope
• Seizure• < 1%• No development of seizure disorders• No medical complications
tmshealthsolutions.com
FDA Approved Target for Depression
tmshealthsolutions.com
Overall Summary of Effectiveness in Major Depression
• 4 large, multisite, randomized controlled trials demonstrated clinically significant antidepressant effect of TMS
(2 industry, 1 by NIH, 1 European augmentation study)
• Prospective, naturalistic RCT confirms these results in real-world practice settings
• Efficacy in private practice data
• Remission rates from 15%-30% in the double-blind phase, and 30% or more in open-label
• Overall, 1 in 2 patients respond and 1 in 3 patients achieve remission
• TMS is, generally, associated with a high level of treatment adherence, >80% of patients completed acute treatment in
both research setting and in clinical practice
George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Archives of General Psychiatry 67, 507-516, 2010Herwig U, Fallgatter AJ, Hoppner J, et al. Antidepressant effects of augmentative transcranial magnetic stimulation: randomized multicentre trial. British Journal Psychiatry, 191, 441-448, 2007Levkovitz Y, Isserles M, Padberg F, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry 14, 64-73, 2015O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation for the acute treatment of major depression: a multisite randomized controlled trial. Biological Psychiatry, 62, 1208-1216, 2008
7/15/19
5
tmshealthsolutions.com
• Exposure and response prevention first line for non-comorbid/mild OCD
• Medications:
• Fluoxetine
• Paroxetine
• Sertraline
• Fluvoxamine
• Clomipramine
Above treatments result in ≥30% improvement for 40-60% of OCD patients
Current Approved Treatments for OCD
tmshealthsolutions.com
Cortico-Striato-Thalamo-Cortical (CSTC) loops
Orbitofrontal Cortex (OFC)Anterior Cingulate Cortex (ACC)Ventromedial Prefrontal Cortex (VMPFC)
Dorsomedial Prefontral Cortex (DMPFC)Supplementary Motor Area (SMA)Ventral Striatum (VS) (accumbens, caudate)
Thalamus
Amygdala & Bed Nucleus of Stria Terminalis (BNST)
Implicated Brain Targets
tmshealthsolutions.com
ACC acts as hub connected to 3 key networks (Salience, Reward, & Non-Reward) via CSTC loops
fMRI studies show pain, negative affect, and cognitive control all activate an overlapping region of the dACC, processing negative emotional and reinforcing information and then directing motivated behavior.
The estimator of “Expected Value of Control” (EVC)• control signals can indicate “identity” & “intensity”
• control signal passed to “regulatory centers” (DLPFC & others)
ACC control signals are used to exert top-down control over downstream effectors of a chosen behavior:
• problem solving and correction
• assessing salience of stimuli & emotion• assessing motivational information
• role in conditioning, harm expectancy, extinction
ANTERIOR CINGULATE CORTEX (ACC)
Source: McGovern, 2017
7/15/19
6
tmshealthsolutions.com
Mis-specified control signals - > persistent anxiety-producing sense of threat or unease generated by otherwise innocuous stimuli that cannot be extinguished.
Repetitive behaviors to reduce this distress signal are ineffective, but the individual persists with these maladaptive behaviors, unable to abandon them and switch to more useful strategies.
Ex. 1: Overestimating the threat of germs and exaggerating the importance of the act of cleaning lead to contamination obsessions and washing compulsions. Unable to quench the feeling of threat from the contaminant, the individual continues to perform the exaggerated cleansing rituals.
DORSAL ACC ABERRANT CONTROL SIGNAL HYPOTHESIS
Source: McGovern, 2017
tmshealthsolutions.com
• Impaired ability to inhibit intrusive thoughts, urges, feelings, and behaviors (motor control & response inhibition)
• decreased interneuron inhibitory behavior in striatum
• Decreased connectivity/activity in cognitive control/ Salience Network
• Inappropriate automatic & subconscious threat responses or inappropriately sustained threat responses• mis-specification of control signal identity & intensity
• exaggerated amygdala or BNST response to threat
• Decreased ability to effortfully correct behavior, learn, adapt, extinguish fear (affective & reward processing)
• dysregulation of medial & lateral OFC & mis-specification of control signal identity & intensity
• Get stuck in worsening re-entry loops of obsessions in search of reward• dysregulation of lateral OFC & its connection to amygdala & reward circuits
• Dysregulated evaluation of punishment over reward • dysfunction at ACC, Reward network, &/or Non-Reward network
IN SUMMARY, OCD PATIENTS DEMONSTRATE:
tmshealthsolutions.com
TMS for OCD
• Non-invasive, minimal side effects
• Standard depression protocols do not seem to consistently work in OCD
• Promising studies targeting SMA, DMPFC/ACC, and OFC
• Deeper TMS could allow greater variety of brain structures to be targeted
• Recent FDA Clearance for Brainsway H7 dTMS device in Aug 2018
7/15/19
7
tmshealthsolutions.com
Supplementary Motor Area (SMA)
https://neuroscientificallychallenged.com/glossary/supplementary-motor-area
tmshealthsolutions.com
Dorsomedial Prefrontal Cortex (DMPFC) &Anterior Cingulate Cortex (ACC)
Daskalakis et al (2016). Zangen et al (2016).
*Only FDA cleared target for OCD.
tmshealthsolutions.com
Lateral Orbitofrontal Cortex (OFC)
Ruffini et al., 2009; Nauczyciel et al.,2014
7/15/19
8
tmshealthsolutions.com
• Effects of TMS may be more pronounced when the targeted circuit is active. (addiction, PTSD, smoking)
• Items that are stored in long-term memory become prone to change (stimulation) upon retrieval (following provocation)
• Personal provocations/hierarchy designed by treating clinician &/or therapist prior to Tx
• OCD symptoms provoked for each subject using internal or external stimuli to induce the typical OCD sx and distress in that individual
• Provocation/exposure done at beginning or just prior to treatment
• Provocations should aim to achieve score of 4-7 on 10 point Visual analog scale (VAS) before proceeding with stimulation
Carmi, 2017; Dinur-Klein, 2014; Isserles, 2013
PROVOCATION OF OCD SYMPTOMS
tmshealthsolutions.com
MULTICENTER OCD STUDY
USA-Mt. Sinai Medical Center-Neuropharmacology Services -University of California, Los Angeles-University of California, San Diego-University of Florida-University of Chicago-Advanced Mental Health Care -Linder Center of Hope-TMS Hope Center Long Island
CANADA- Center for Addiction and Mental Health
ISRAEL-Tel Hashomer Hospital
11 sites from North America and Europe
PI: Joseph Zohar MD, Abraham Zangen PhD
A Prospective Double Blind Randomized Controlled Study to Evaluate the Safety and Efficacy of H7
Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects who Failed SSRIs
Led to FDA Clearance of Brainsway H7 device to treat OCD in Aug 2018
Carmi et al. (2019)
tmshealthsolutions.com
BrainsWay H7 Coil Targets the DMPFC and ACC
7/15/19
9
tmshealthsolutions.com
FDA Target for Depression
Standard depression protocols do not seem to work for OCD based on current evidence
FDA Target for OCD
Dorsomedial Prefrontal cortex
Anterior Cingulate Cortex (ACC)
tmshealthsolutions.com
INCLUSION CRITERIA DEMOGRAPHICS
• 94 patients met inclusion criteria
• 58% Male, 75% Caucasian
• Prior meds 98% (19% took 5 SSRI’s), Prior CBT 69%
• Family hx OCD 55%
• Outpatients, men and women 22-68 years of age
• Subjects with at least moderate OCD (Y-BOCS score of ≥ 20)
• Maintained on SSRI’s at a therapeutic dosage for at least 2 months prior to study entry and for the duration of the trial
• and/or maintained on psychotherapeutic behavioral interventions in the maintenance stage (i.e. not during the assessment or skills acquisition or training stages)
Primary Objective: Change in Y-BOCS between the active and sham treatments groups at 6 wks
• Response Rate –reduction of at least 30% in YBOCS score from baseline
• Partial Response Rate – reduction of at least 20% in YBOCS score from
• Remission Rate – defined as YBOCS score < 10
Carmi et al. (2019)
tmshealthsolutions.com
AVERAGE IMPROVEMENT IN YBOCS SCORES
Carmi et al. (2019)
7/15/19
10
tmshealthsolutions.com
38%
11%
55%
27%
Full response (> 30%) Partial response (> 20%)
RESPONSE RATES IN ACTIVE VS SHAM DEEP TMS
Carmi et al. (2019)
tmshealthsolutions.com
MEAN CHANGE IN YBOCS FROM BASELINEMEDICATION TRIALS VS DEEP TMS TRIAL
Data on SSRI medications based on meta-analysis (Soomro et al., 2008)
4.47
5.57
7
5.55
6.7
1.4
3.123.64
1.68
3.6
∆=3.1
∆=3.87
∆=3.36
∆=2.45
∆=3.07
Dark = TreatmentLight = Sham
Carmi et al. (2019)
tmshealthsolutions.com
TMS HEALTH SOLUTIONS
Private Practice Outcomes
*Results to be shown during conference presentation
7/15/19
11
tmshealthsolutions.com
WHO IS RIGHT FOR TREATMENT AND IS TMS COVERED BY INSURANCE?
FDA Indicated for Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from a prior antidepressant medication at or above the minimal effective dose and duration in the current episode. Insurance currently covers treatment but can vary in requirements by plan.
Brainsway H7 dTMS FDA cleared for OCD treatment but most insurance companies have not written their policies yet.
Patient Characteristics:
• In a recurrent or chronic episode
• Multiple medication attempts, yet still symptomatic
• Experiences frequent side effects from medication
• Obsessions/compulsions impede ability to use medications
• Inadequate response to exposure response prevention
tmshealthsolutions.com
SUMMARY & CONCLUSIONS:
• TMS is safe, non-invasive, & has been FDA approved for MDD for the last 10 years.
• 2018 - FDA clearance for OCD specifically for the Brainsway H7 system
• Multiple targets & protocols being explored: SMA, OFC, DMPFC/ACC, & low vs high freq
• Exposure/Provocation protocol is unique to OCD treatment and may enhance outcomes
• In treatment resistant OCD, TMS is a reasonable, low-risk, evidence-based option to prescribe
• Many clinicians already using TMS will likely be looking to provide this treatment, but may not have sufficient OCD experience to appropriately tailor treatment to individual patients. Having experienced OCD clinicians who also feel comfortable with TMS, or having TMS clinicians partner with experienced OCD clinicians, will be important in translating clinical trial results to actual real world results.
tmshealthsolutions.com
Questions ?
7/15/19
12
tmshealthsolutions.com
Dougherty, D.D. & Ahmari, S.E. (2015). Dissecting OCD Circuits: From Animal Models to Targeted Treatments
Dougherty, D. D. et al. (2018). Neuroscientifically Informed Formulation and Treatment Planning for Patients With Obsessive-Compulsive Disorder: A Review.
Ting, J.T. & Feng, G. (2011). Neurobiology of Obsessive-Compulsive Disorder: Insights into Neural Circuitry Dysfunction through Mouse Genetics. Fettes, Schulze, Downar (2017). Cortico-Striatal-Thalamic Loop Circuits of the Orbitofrontal Cortex: Promising Therapeutic Targets in Psychiatric Illness
Berlim et al (2013). Repetitive transcranial magnetic stimulation (rTMS) for obsessive compulsive disorder (OCD): An exploratory meta-analysis of randomized and sham-controlled trials
Zhou et al (2017). An updated meta-analysis: Short-term therapeutic effects of repeated transcranial magnetic stimulation in treating Obsessive Compulsive Disorder
Rehn et al (2018). A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD)
Downar (Dec 5, 2017 CTMSS Grand Rounds). Beyond One Size Fits All: Tailoring the rTMS Protocol to the patient.
Dunlop, Hanlon, Downar (2016) Noninvasive brain stimulation treatments for addiction and major depressionBloch et al (2010). Meta-Analysis of the Dose-Response Relationship of SSRI in Obsessive-Compulsive Disorder.
Pittenger, C., & Bloch, M. H. (2014). Pharmacological Treatment of Obsessive-Compulsive Disorder
Hollander et al. (2016). The cost and impact of compulsivity: A research perspective.
Soomro et al (2008). Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).
References
tmshealthsolutions.com
Ruffini et al (2009). Augmentation Effect of Repetitive Transcranial Magnetic Stimulation Over the Orbitofrontal Cortex in Drug-Resistant Obsessive-Compulsive Disorder Patients: A Controlled Investigation
Nauczyciel (2014). Repetitive transcranial magnetic stimulation over the orbitofrontal cortex for obsessive-compulsive disorder: a double-blind, crossover study
Dunlop et al (2016). Reductions in Cortico-Striatal Hyperconnectivity Accompany Successful Treatment of Obsessive-Compulsive Disorder with Dorsomedial Prefrontal rTMS
Dunlop, Hanlon, Downar (2016) Noninvasive brain stimulation treatments for addiction and major depression
Carmi et al (2017). Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patientsZangen et al (2016). Deep TMS of the Anterior Cingulate Cortex in OCD patients
Daskalakis et al (2016). Validation of a 25% Nasion–Inion Heuristic for Locating the Dorsomedial Prefrontal Cortex for Repetitive Transcranial Magnetic Stimulation
Holbert and Witter (2017) Positive clinical response to treatment of obsessive–compulsive disorder using dual-site transcranial magnetic stimulationDinur-Klein et al (2014). Smoking Cessation Induced by Deep Repetitive Transcranial Magnetic Stimulation of the Prefrontal and Insular Cortices: A Prospective, Randomized Controlled Trial. Isserles et al (2013). Effectiveness of Deep Transcranial Magnetic Stimulation Combined with a Brief Exposure Procedure in Post-Traumatic Stress Disorder – A Pilot Study. Tendler et al. (2018). O14. Deep TMS of the Medial Prefrontal and Anterior Cingulate Cortices for OCD: A Double-Blinded Multi-Center Study.
Carmi et al. (2019) Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective multicenter double-blind placebo-controlled trial
References
tmshealthsolutions.com
top related